IGF-1 signaling promotes myeloma cell survival and progression [202–207], whereas inhibition of IGF-1 signaling promotes the pro-apoptotic effects of chemotherapeutic drugs in MM. The gene discussed is IGF1; the disease is plasma cell myeloma.